Quinoa bran terpenoids ameliorates metabolic dysfunction-associated steatotic liver disease by enriching of L. murinus LQ719.

Metabolic dysfunction-associated steatotic liver disease (MASLD) is a chronic liver disease associated with insulin resistance and obesity. Plant triterpenoids possess the efficacies of regulating insulin resistance, inhibiting lipid production, and reducing oxidative damage, which are a type of potential active molecules for anti-MASLD. In present study, we novelly found quinoa bran terpenoids (QBT) exhibits a remarkable anti-MASLD activity, manifested as the reduction of hepatic lipid deposition, alleviation of abnormal glycolipid metabolism and decrease of inflammatory response. Further, the microbial sequencing results revealed that QBT remodels the gut microbiota structure of high-fat diet (HFD) induced MASLD mice, reducing the proportion of Firmicutes/Bacteroidetes at the phylum level, and specifically, significantly enriching Lactobacillus at the genus level. Subsequently, a novel Lactobacillus murinus was identified from fecal samples of QBT treated mice and named L. murinus LQ719 (NCBI sequence accession No. PV608014.1). Expectedly, the anti-MASLD activity of L. murinus LQ719 was confirmed in MASLD mice induced by HFD.It suggests that L. murinus LQ719 plays the crucial role in the anti-MASLD effect induced by QBT. Hence, the study provided a theoretical basis for the development of QBT as a dietary supplement for alleviating MASLD.